The Washington Post looks at unexpected effects people report on GLP-1 drugs, some of which it calls revolutionary.
Recap by typeshit. Full story at The Washington Post.
The actor backed Ozempic in an interview while saying exercise has no shortcut. Doctors break down whether his advice holds up.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
Dr Nadolsky, who treats obesity, responds to what wellness influencer Gary Brecka has said about GLP-1 medications.
South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
Loading…